| 0.7775 0.008 (0.97%) | 10-05 11:26 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.1  |
1-year : | 1.23 |
| Resists | First : | 0.94 |
Second : | 1.05 |
| Pivot price | 0.87 |
|||
| Supports | First : | 0.76 | Second : | 0.63 |
| MAs | MA(5) : | 0.79 |
MA(20) : | 0.9 |
| MA(100) : | 1.02 |
MA(250) : | 2.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.1  |
D(3) : | 3.3 |
| RSI | RSI(14): 29 |
|||
| 52-week | High : | 6.76 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ REVB ] has closed above bottom band by 13.5%. Bollinger Bands are 42% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.81 - 0.82 | 0.82 - 0.82 |
| Low: | 0.75 - 0.75 | 0.75 - 0.76 |
| Close: | 0.75 - 0.76 | 0.76 - 0.77 |
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipeline includes promising candidates such as GEM-AKI, which is being developed as a potential therapy for both the prevention and management of acute kidney injury, and GEM-CKD, intended for the prevention and treatment of chronic kidney disease. Established in 2019, this San Diego, California-based enterprise was formerly known as Petra Acquisition, Inc., before officially adopting the name Revelation Biosciences, Inc. in January 2022.
Fri, 04 Sep 2026
Revelation Biosciences Inc (NYSE: REVB) Share Price, REVB Stock News, REVB Share Price & Updates - kalkine.ca
Wed, 19 Aug 2026
Revelation Biosciences grants restricted shares to James Rolke and Chester S. Zygmont III - TradingView
Tue, 18 Aug 2026
Revelation Biosciences (NASDAQ: REVB) grants director 32K restricted shares - Stock Titan
Thu, 06 Aug 2026
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026 - Yahoo Finance
Fri, 31 Jul 2026
Revelation Biosciences (NASDAQ:REVB) secures FDA agreement setting single-study path for kidney drug Gemini - Kalkine
Fri, 10 Jul 2026
Revelation Biosciences Announces Adoption of Stockholder Rights Plan - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 12.3 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | 27.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -78.8 % |
| Return on Equity (ttm) | -154.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.83 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 0.02 |
| PEG Ratio | 0 |
| Price to Book value | 0.3 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|